FDA approves new prescription antibiotic option for cattle, pigs
The antibiotic treats organisms associated with BRD, foot rot and pinkeye
21 March 2022
2 minute read
By: Earlier this month, Merck Animal Health, known as MSD Animal Health outside the United States and Canada, announced it had received US FDA approval of AROVYN, a broad-spectrum, prescription antibiotic that treats the major organisms associated with bovine respiratory disease (BRD), foot rot and pinkeye.
“Merck Animal Health is pleased to add AROVYN to our comprehensive, trusted portfolio of cattle antimicrobials. AROVYN gives veterinarians a new option when prescribing tulathromycin, which is proven to help treat some of the most common and costly cattle disease challenges,” said David Sjeklocha, technical services manager, Merck Animal Health. “While adhering to vaccination protocols can certainly help keep animals healthy, some animals still will get sick. New AROVYN is for those situations requiring early diagnosis and an effective treatment program, so animals can recover quickly.”
In beef and non-lactating dairy cattle, AROVYN is indicated for the treatment of BRD and control of respiratory disease in animals at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis.
It also is approved for treatment of pinkeye or infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis, plus treatment of foot rot associated with Fusobacterium necrophorum and Porphyromonas levii. In suckling calves, dairy calves and veal calves, AROVYN is indicated for treatment of BRD associated with M. haemolytica, P. multocida, H. somni and M. bovis.
AROVYN, which is suitable for both cattle and swine, will be available from or on the order of a licensed veterinarian starting in May 2022.
